292 related articles for article (PubMed ID: 12145798)
1. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease.
Tibble JA; Sigthorsson G; Foster R; Forgacs I; Bjarnason I
Gastroenterology; 2002 Aug; 123(2):450-60. PubMed ID: 12145798
[TBL] [Abstract][Full Text] [Related]
2. [Fecal calprotectin in differential diagnosis of irritable bowel syndrome].
Li XG; Lu YM; Gu F; Yang XL
Beijing Da Xue Xue Bao Yi Xue Ban; 2006 Jun; 38(3):310-3. PubMed ID: 16778979
[TBL] [Abstract][Full Text] [Related]
3. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease.
Tibble JA; Sigthorsson G; Bridger S; Fagerhol MK; Bjarnason I
Gastroenterology; 2000 Jul; 119(1):15-22. PubMed ID: 10889150
[TBL] [Abstract][Full Text] [Related]
4. Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal inflammation.
Chung-Faye G; Hayee B; Maestranzi S; Donaldson N; Forgacs I; Sherwood R
Inflamm Bowel Dis; 2007 Nov; 13(11):1374-8. PubMed ID: 17577247
[TBL] [Abstract][Full Text] [Related]
5. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic accuracy of faecal calprotectin estimation in prediction of abnormal small bowel radiology.
Dolwani S; Metzner M; Wassell JJ; Yong A; Hawthorne AB
Aliment Pharmacol Ther; 2004 Sep; 20(6):615-21. PubMed ID: 15352909
[TBL] [Abstract][Full Text] [Related]
7. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS.
Menees SB; Powell C; Kurlander J; Goel A; Chey WD
Am J Gastroenterol; 2015 Mar; 110(3):444-54. PubMed ID: 25732419
[TBL] [Abstract][Full Text] [Related]
8. Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease.
Bunn SK; Bisset WM; Main MJ; Golden BE
J Pediatr Gastroenterol Nutr; 2001 Feb; 32(2):171-7. PubMed ID: 11321388
[TBL] [Abstract][Full Text] [Related]
9. Fecal calprotectin: a significant step in the noninvasive assessment of intestinal inflammation.
Bjarnason I; Sherwood R
J Pediatr Gastroenterol Nutr; 2001 Jul; 33(1):11-3. PubMed ID: 11479401
[No Abstract] [Full Text] [Related]
10. Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children.
Sidler MA; Leach ST; Day AS
Inflamm Bowel Dis; 2008 Mar; 14(3):359-66. PubMed ID: 18050298
[TBL] [Abstract][Full Text] [Related]
11. Semiquantitative fecal calprotectin test in postinfectious and non-postinfectious irritable bowel syndrome: cross-sectional study.
David LE; Surdea-Blaga T; Dumitrascu DL
Sao Paulo Med J; 2015; 133(4):343-9. PubMed ID: 26039537
[TBL] [Abstract][Full Text] [Related]
12. Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome.
Sydora MJ; Sydora BC; Fedorak RN
J Crohns Colitis; 2012 Mar; 6(2):207-14. PubMed ID: 22325175
[TBL] [Abstract][Full Text] [Related]
13. High prevalence of NSAID enteropathy as shown by a simple faecal test.
Tibble JA; Sigthorsson G; Foster R; Scott D; Fagerhol MK; Roseth A; Bjarnason I
Gut; 1999 Sep; 45(3):362-6. PubMed ID: 10446103
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic accuracy of point-of-care fecal calprotectin and immunochemical occult blood tests for diagnosis of organic bowel disease in primary care: the Cost-Effectiveness of a Decision Rule for Abdominal Complaints in Primary Care (CEDAR) study.
Kok L; Elias SG; Witteman BJ; Goedhard JG; Muris JW; Moons KG; de Wit NJ
Clin Chem; 2012 Jun; 58(6):989-98. PubMed ID: 22407858
[TBL] [Abstract][Full Text] [Related]
15. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma.
Tibble J; Sigthorsson G; Foster R; Sherwood R; Fagerhol M; Bjarnason I
Gut; 2001 Sep; 49(3):402-8. PubMed ID: 11511563
[TBL] [Abstract][Full Text] [Related]
16. Fecal dimeric M2-pyruvate kinase (tumor M2-PK) in the differential diagnosis of functional and organic bowel disorders.
Jeffery J; Lewis SJ; Ayling RM
Inflamm Bowel Dis; 2009 Nov; 15(11):1630-4. PubMed ID: 19462434
[TBL] [Abstract][Full Text] [Related]
17. A simple method for assessing intestinal inflammation in Crohn's disease.
Tibble J; Teahon K; Thjodleifsson B; Roseth A; Sigthorsson G; Bridger S; Foster R; Sherwood R; Fagerhol M; Bjarnason I
Gut; 2000 Oct; 47(4):506-13. PubMed ID: 10986210
[TBL] [Abstract][Full Text] [Related]
18. Clinical utility of the assessment of fecal calprotectin in Leśniowski-Crohn's disease.
Eder P; Stawczyk-Eder K; Krela-Kaźmierczak I; Linke K
Pol Arch Med Wewn; 2008 Nov; 118(11):622-6. PubMed ID: 19140565
[TBL] [Abstract][Full Text] [Related]
19. Relationship between intestinal permeability and calprotectin concentration in gut lavage fluid.
Berstad A; Arslan G; Folvik G
Scand J Gastroenterol; 2000 Jan; 35(1):64-9. PubMed ID: 10672837
[TBL] [Abstract][Full Text] [Related]
20. Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy.
Limburg PJ; Ahlquist DA; Sandborn WJ; Mahoney DW; Devens ME; Harrington JJ; Zinsmeister AR
Am J Gastroenterol; 2000 Oct; 95(10):2831-7. PubMed ID: 11051356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
